intended audience
This activity was developed for medical oncologists and other health professionals caring for patients with NSCLC.
learning objectives
Upon completion of this activity, participants should be better able to:

Define the state-of-the-art knowledge of advanced NSCLC

Assess the role of newer targeted agents and apply these therapies
appropriately in practice

Evaluate the use of molecular markers in determining proper therapeutic
selection for their patients
accreditation and certification
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education
to provide continuing medical education for physicians.
The Annenberg Center designates this educational activity for a maximum of 1.5 AMA PRA Category 1
Creditstm. Physicians should only claim
credit commensurate with the extent of their participation in the activity.
There is no charge for this activity. Statements of Credit will be mailed 4-6 weeks following activity participation, upon
completion and return of the evaluation form to the Annenberg Center for Health Sciences.
disclosure
It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming.
All faculty participating in sponsored programs are expected to identify and reference off-label product use and disclose any
significant relationship with those supporting the activity or any others whose products or services are discussed. Full disclosure
will be made in the syllabus.
If you need reasonable, special accommodations or have questions about access to any of our activities, please contact Lucy Cole
by phone: 800-321-3690, by fax: 760-773-4550, or by e-mail:
. All requests must be received at least 14 days in advance of the intended activity start date.
This activity is supported by an educational grant from Genentech, Inc.
This activity is based on needs assessment and materials funded by independent educational grans from Boehringer Ingelheim
Pharmaceuticals, Inc.